Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27489178 | 0.98 | MEN1 (0.61) | MEN1KMT2ATDP1HDAC8HDAC3 | |
| Hydrochloric Acid SCHEMBL7823186 | 0.98 | MEN1 (0.61) | MEN1KMT2ATDP1HDAC8HDAC3 | |
| SCHEMBL3669498 | 0.91 | ALDH1A1 (0.56) | MEN1KMT2ATDP1HDAC8HDAC3 | |
| SCHEMBL5939323 | 0.89 | S1PR1 (0.64) | HDAC1GAAALDH1A1FFAR1FFAR4 | |
| SCHEMBL864629 | 0.88 | HDAC3 (0.65) | MEN1KMT2ATDP1HDAC8HDAC3 | |
| Ether SCHEMBL911373 | 0.88 | SMN1; SMN2 (0.51) | MEN1KMT2ATDP1HDAC8HDAC3 | |
| SCHEMBL11300014 | 0.87 | MEN1 (0.48) | MEN1KMT2ATDP1HDAC8HDAC3 | |
| SCHEMBL8905341 | 0.86 | HDAC3 (0.73) | MEN1KMT2ATDP1HDAC8HDAC3 | |
| SCHEMBL1981483 | 0.86 | MEN1 (0.68) | MEN1KMT2ATDP1HDAC8HDAC3 | |
| SCHEMBL7204842 | 0.85 | HDAC3 (0.73) | MEN1KMT2ATDP1HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1880711-B1 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD (JP) | 2016-07-20 | — | — | EP | claimed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | claimed |
| EP-2531487-A1 | ARYL BENZYLAMINE COMPOUNDS | Novartis AG (CH) | 2012-12-12 | — | — | EP | claimed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | claimed |
| CN-102319184-A | Parakeratosis inhibitor, pore contracting agent and composition for external application | SHISEIDO CO LTD | 2012-01-18 | — | — | CN | claimed |
| WO-2011095452-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-11 | — | — | WO | claimed |
| CN-101175470-A | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD (JP) | 2008-05-07 | — | — | CN | claimed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | claimed |
| EP-4739685-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008061-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| EP-4406606-A2 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G | Bayer Pharma Aktiengesellschaft (DE) | 2024-07-31 | — | — | EP | disclosed |
| CN-114369052-A | Synthetic method of 3-aminopyrrolidine dihydrochloride | 赤峰万泽药业股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| WO-2021178488-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-11041048-B2 | Polyhemiaminal and polyhexahydrotriazine materials from 1,4 conjugate addition reactions | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2021-06-22 | — | — | US | disclosed |
| EP-0690862-A1 | NOVEL QUINOLONE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1996-01-10 | — | — | EP | disclosed |
| CN-1106405-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating | THOMAE GMBH DR K (DE) | 1995-08-09 | — | — | CN | disclosed |
| WO-1994015938-A1 | NOVEL QUINOLONE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1994-07-21 | — | — | WO | disclosed |
| EP-0178927-A2 | Compounds, methods for their preparation, and their use in therapy | BIOMEASURE, INC. (US) | 1986-04-23 | — | — | EP | disclosed |
| EP-0051234-B1 | A PROCESS FOR THE PRODUCTION OF A 2-AZETIDINONE DERIVATIVE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-03-13 | — | — | EP | disclosed |
| EP-0051234-A1 | A process for the production of a 2-azetidinone derivative | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1982-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | MEN1 1767/4885KMT2A 4216/4885TDP1 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.